Data Strategies & Transformation Study Results
Drug Developers Respond to Evolving Clinical Data Demands, Prepare for Digital Transformation
Tufts CSDD & eClinical Solutions surveyed more than 140 Life Sciences companies to learn about the impact diverse and external data sources are having on drug developers including current capabilities, data management and analysis activities, competencies and systems, cycle time impacts, and the broader digital transformation strategies.
The results include:
- How sponsors are managing the rapidly evolving data landscape
- The impact of data diversity on performance and efficiency
- New capabilities and competencies companies are implementing to address the changing landscape
Watch and learn from the on-demand webinar which shares results, study methods, key takeaways and insights.
Ken Getz of the Tufts Center for the Study of Drug Development (CSDD)
Respondents with a formalized data strategy reported less difficulty with data activities such as ingesting, integrating and analyzing data and a two week time cycle time advantage.
Learn More & Share the Tufts CSDD-eClinical Study Results
Apply insights from the study to your organization with a more personalized in-depth review of the study results. Contact us for a tailored, live presentation of the Tufts CSDD-eClinical study data for you and your colleagues.
How does your organization compare?
If you are looking for help in making a case for why your organization needs a formalized data strategy or to understand how your organization aligns with those organizations that are prepared to take advantage of advanced analytics, AI and machine learning, the data from this study can help.